Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials

• Narikazu Boku,
• Amit Roy,
• Yan Feng,
• Paul Nghiem,
• Yoon-Koo Kang,
• Martin Reck,
• Li-Tzong Chen,
• Taofeek K Owonikoko,
• Hye Ryun Kim,
• Ming Lei,
• Gregory Plautz,
• Han Chang,
• Wen Hong Lin,
• Akintunde Bello,
• Jennifer Sheng

Affiliations

Narikazu Boku

Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

Amit Roy

Aff1 grid.419971.3Clinical Pharmacology and Pharmacometrics, Exploratory Clinical and Translational ResearchBristol-Myers Squibb Co. 3551 Lawrenceville Road 08543 Princeton NJ USA

Yan Feng

Pragmatic Clinical Trials Unit, Queen Mary University of London, London, UK

Paul Nghiem

Division of Dermatology, University of Washington Medical Center at South Lake Union, Seattle, Washington, USA

Yoon-Koo Kang

10 Asan Medical Center, Seoul, South Korea

Martin Reck

Lungen Clinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany

Li-Tzong Chen

6National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan

Taofeek K Owonikoko

Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, Georgia, USA

Hye Ryun Kim

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea

Ming Lei

Aging Research Institute

Gregory Plautz

Medical Safety Assessment, Bristol Myers Squibb, Princeton, New Jersey, USA

Han Chang

Translational Bioinformatics, Bristol Myers Squibb, Princeton, New Jersey, USA

Wen Hong Lin

Oncology Clinical Development, Bristol Myers Squibb, Princeton, New Jersey, USA

Akintunde Bello

Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA

Jennifer Sheng

Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, New Jersey, USA